

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

<p>SANOFI-AVENTIS U.S. LLC, AVENTISUB LLC, SANOFI, and GENZYME CORPORATION,</p> <p style="text-align: center;">Plaintiffs,</p> <p style="text-align: center;">v.</p> <p>GLENMARK PHARMACEUTICALS INC., USA, GLENMARK PHARMACEUTICALS SA, and GLENMARK PHARMACEUTICALS LIMITED,</p> <p style="text-align: center;">Defendants.</p>	<p>Civil Action No.</p>
---	-------------------------

COMPLAINT

Plaintiffs sanofi-aventis U.S. LLC (“sanofi-aventis U.S.”), Aventisub LLC (“Aventisub”), Sanofi, and Genzyme Corporation (“Genzyme”) (collectively, “Plaintiffs”), by their attorneys, for their Complaint against Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals SA, and Glenmark Pharmaceuticals Limited (“Defendants”), allege as follows:

NATURE OF THE ACTION

1. This is a civil action for infringement of United States Patent Nos. 6,794,410 (“the ‘410 patent,” a true and accurate copy of which is attached hereto as Exhibit A) and 9,186,346 (“the ‘346 patent,” a true and accurate copy of which is attached hereto as Exhibit B) arising under the Patent Laws of the United States, Title 35, United States Code, Sections 100 *et seq.* This action relates to Abbreviated New Drug Application (“ANDA”) No. 209663, filed by Glenmark Pharmaceuticals Inc. USA and Glenmark Pharmaceuticals SA with the United States

Food and Drug Administration (“FDA”) for approval to market a proposed generic version of the Aubagio® (teriflunomide) drug product.

THE PARTIES

2. Plaintiff sanofi-aventis U.S., a wholly-owned U.S. subsidiary of Sanofi, is a limited liability company organized and existing under the laws of the State of Delaware, having its principal place of business at 55 Corporate Drive, Bridgewater, New Jersey 08807.

3. Plaintiff Aventisub LLC is a limited liability company organized and existing under the laws of the State of Delaware, having its principal place of business at 3711 Kennett Pike, Suite 200, Greenville, Delaware 19807.

4. Plaintiff Sanofi is a corporation organized and existing under the laws of France, having its principal place of business at 54 rue La Boétie, 75008 Paris, France.

5. Plaintiff Genzyme is a corporation organized and existing under the laws of the State of Massachusetts, having its principal place of business at 500 Kendall Street, Cambridge, Massachusetts 02142.

6. On information and belief, Defendant Glenmark Pharmaceuticals Inc., USA (“Glenmark USA”) is a company organized and existing under the laws of the State of Delaware with its principal place of business at 750 Corporate Drive, Mahwah, New Jersey 07430. On information and belief, Glenmark USA is in the business of, among other things, developing, formulating, manufacturing, marketing and selling generic versions of branded pharmaceutical products for the United States market and in this judicial district, alone and/or through its wholly-owned subsidiaries and agents. On information and belief, Glenmark USA is a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, is controlled by Glenmark Pharmaceuticals Limited, and is an agent or affiliate of Glenmark Pharmaceuticals Limited.

7. On information and belief, Defendant Glenmark Pharmaceuticals SA (“Glenmark SA”) is a company organized and existing under the laws of Switzerland, with a principal place of business at 2nd Floor, Swisscom Building, Rue de la Maladiere 23, Neuchâtel, 2000, Switzerland. On information and belief, Glenmark SA is in the business of researching, developing, formulating, manufacturing, and selling generic versions of pharmaceutical products for the United States market and in this judicial district, alone and/or through its wholly-owned subsidiaries and agents. On information and belief, Glenmark SA is a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, is controlled by Glenmark Pharmaceuticals Limited, and is an agent or affiliate of Glenmark Pharmaceuticals Limited.

8. On information and belief, Defendant Glenmark Pharmaceuticals Limited (“Glenmark Ltd.”) is a company organized and existing under the laws of India, having a principal place of business at Glenmark House, HDO-Corporate Building, Wing -A, B D Sawant Marg, Chakala, Off Western Express Highway, Mumbai 400099, Maharashtra, India. On information and belief, Glenmark Ltd. is in the business of researching, developing, formulating, manufacturing, selling generic versions of pharmaceutical products for the United States market and in this judicial district. On information and belief, Glenmark USA is the North American division of Glenmark Ltd.

9. On information and belief, Glenmark SA and Glenmark Ltd. operate in the United States through Glenmark USA.

10. On information and belief, the acts of Glenmark USA and Glenmark SA complained of herein were done at the direction of, with the authorization of, and/or with the cooperation, participation, and assistance of Glenmark Ltd. On information and belief, the acts

of Glenmark USA and Glenmark SA complained of herein were done at least in part for the benefit of Glenmark Ltd.

GLENMARK USA AND GLENMARK SA'S ANDA

11. On information and belief and as stated in the letter dated November 16, 2016, and received by Plaintiffs on or about November 18, 2016, purporting to be a notice pursuant to Section 505(j)(2)(B)(ii) and (iv) of the Federal Food Drug and Cosmetic Act (21 U.S.C. § 355(j)) and 21 C.F.R. § 314.95(c) (the “Notice Letter”), Glenmark USA, on behalf of Glenmark SA, submitted ANDA No. 209663 to the FDA under Section 505(j) of the Federal Food Drug and Cosmetic Act (21 U.S.C. § 355(j)) seeking approval to engage in the commercial manufacture, use, sale and/or importation of teriflunomide tablets, 7 mg and 14 mg (“Teriflunomide ANDA Products”), as a generic version of the Aubagio[®] (teriflunomide) drug product throughout the United States, including within the State of Delaware, prior to the expiration of the ‘410 and ‘346 patents.

JURISDICTION AND VENUE

12. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

13. On information and belief, Glenmark USA and Glenmark SA, with the assistance and/or direction of Glenmark Ltd., develop, formulate, manufacture, import, offer for sale, sell, commercialize, market, and/or distribute generic versions of branded pharmaceutical products in/into the United States, including in the State of Delaware.

14. On information and belief, Glenmark USA prepared and filed ANDA No. 209663 on behalf of Glenmark SA, seeking approval from the FDA to sell the Teriflunomide ANDA Products throughout the United States, including within the State of Delaware.

15. On information and belief, Glenmark Ltd. participated in the preparation and/or filing of ANDA No. 209663, seeking approval from the FDA to sell Teriflunomide ANDA Products throughout the United States, including within the State of Delaware.

16. This Court has personal jurisdiction over Defendants because, *inter alia*, they have committed an act of patent infringement under 35 U.S.C. § 271 (e)(2), and intend a future course of conduct that includes acts of patent infringement in Delaware. These acts have led and will lead to foreseeable harm and injury to Plaintiffs in Delaware. For example, on information and belief, following approval of ANDA No. 209663, Defendants will work in concert to make, use, import, sell, and/or offer for sale the Teriflunomide ANDA Products in/into the United States, including in this State, prior to the expiration of the '410 patent.

17. This Court has personal jurisdiction over Glenmark USA because, *inter alia*, Glenmark USA, on information and belief: (1) maintains substantial, systematic, and continuous contacts with the State of Delaware; (2) avails itself of the laws of the State of Delaware by being incorporated in Delaware under File No. 3600881; (3) intends to manufacture, market, sell, or distribute the Teriflunomide ANDA Products to residents of this State, which is confirmed by the filing of ANDA No. 209663; (4) holds a Pharmacy Wholesale License from the State of Delaware under License No. A4-0001391 and Distributor/Manufacturer License for controlled substances from the State of Delaware under License No. DM-0006376; (5) maintains a broad distributorship network within this State; (6) regularly transacts and/or solicits business in the State of Delaware; (7) continuously and systematically places goods into the stream of commerce for distribution in the United States, including in the State of Delaware; (8) generates substantial revenue and income from sales of its generic pharmaceutical products throughout the United States, including within the State of Delaware.

18. Additionally, on information and belief, Glenmark USA has previously consented to this Court's jurisdiction and has availed itself of the protections afforded by the Court by asserting counterclaims against plaintiffs in this judicial district. *See e.g., GlaxoSmithKline LLC et al. v. Glenmark Pharmaceuticals Inc., USA*, Civil Case No. 14-cv-00877-LPS-CJB (D. Del.); *Sanofi et al v. Glenmark Pharmaceuticals Inc. USA et al.*, Civil Case No. 15-cv-01206-RGA (D. Del.). On information and belief, Glenmark USA's predecessor company, Glenmark Generics Inc. USA, has previously consented to this Court's jurisdiction and has availed itself of the protections afforded by the Court by asserting counterclaims against plaintiffs in this judicial district. *See e.g., Millennium Pharmaceuticals Inc. v. Glenmark Pharmaceuticals Ltd. et al.*, Civil Case No. 14-cv-01156-GMS (D. Del.)

19. This Court has personal jurisdiction over Glenmark SA because, *inter alia*, Glenmark SA, on information and belief: (1) maintains substantial, systematic, and continuous contacts with the State of Delaware, including, but not limited to, ongoing communications and contacts with Glenmark USA; (2) avails itself of the laws of the State of Delaware and engages in a course of conduct in the State of Delaware by at least its interactions with Glenmark USA; (3) intends to manufacture, market, sell, or distribute the Teriflunomide ANDA Products to residents of this State, which is confirmed by the filing of ANDA No. 209663; (4) maintains a broad distributorship network within this State; (5) regularly transacts and/or solicits business in the State of Delaware; (6) continuously and systematically places goods into the stream of commerce for distribution in the United States, including in the State of Delaware; (7) generates substantial revenue and income from sales of its generic pharmaceutical products throughout the United States, including within the State of Delaware.

20. This Court has personal jurisdiction over Glenmark Ltd. because, *inter alia*, Glenmark Ltd., on information and belief: (1) maintains substantial, systematic, and continuous contacts with the State of Delaware, including, but not limited to, ongoing communications and contacts with its U.S. Subsidiary, Glenmark USA; (2) avails itself of the laws of the State of Delaware and engages in a course of conduct in the State of Delaware by at least its U.S. subsidiary, Glenmark USA; (3) intends to manufacture, market, sell, or distribute the Teriflunomide ANDA Products to residents of this State; (4) maintains a broad distributorship network within this State; (5) regularly transacts and/or solicits business in the State of Delaware; (6) continuously and systematically places goods into the stream of commerce for distribution in the United States, including in the State of Delaware; (7) generates substantial revenue and income from sales of its generic pharmaceutical products throughout the United States, including within the State of Delaware.

21. Additionally, on information and belief, Glenmark Ld. has previously consented to this Court's jurisdiction and has availed itself of the protections afforded by the Court by asserting counterclaims against plaintiffs in this judicial district. *See e.g., Millennium Pharmaceuticals Inc. v. Glenmark Pharmaceuticals Ltd. et al.*, Civil Case No. 14-cv-01156-GMS (D. Del.); *Sanofi et al. v. Glenmark Pharmaceuticals Inc. USA et al.*, Civil Case No. 15-cv-01206-RGA (D. Del.).

22. On information and belief, Glenmark USA and Glenmark Ltd. have previously availed themselves of this forum by filing lawsuits in this judicial district as a plaintiff, including at least *Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd. v. GlaxoSmithKline PLC et al.*, Civil Case No. 13-cv-00135-GMS (D. Del.).

23. Alternatively, to the extent the above facts do not establish personal jurisdiction over Glenmark SA and Glenmark Ltd., this Court may exercise jurisdiction over Glenmark SA and Glenmark Ltd. pursuant to Fed. R. Civ. P. 4(k)(2) because: (a) Plaintiffs' claims arise under federal law; (b) Glenmark SA and Glenmark Ltd. would be a foreign defendants not subject to personal jurisdiction in the courts of any State; and (c) Glenmark SA and Glenmark Ltd. have sufficient contacts with the United States as a whole, including, but not limited to, manufacturing and selling generic pharmaceutical products that are distributed throughout the United States, such that this Court's exercise of jurisdiction over Glenmark SA and Glenmark Ltd. satisfies due process.

24. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

THE PATENTS

25. The '410 patent, titled "Use of (Z)-2-cyano-3-hydroxy-but-2-enoic Acid-(4'-trifluoromethylphenyl)-amide for Treating Multiple Sclerosis," was duly and legally issued on September 21, 2004 to inventor Joseph Wettstein. The '410 patent was assigned to Aventis Pharmaceuticals Inc. On July 31, 2013, the United States Patent and Trademark Office granted reexamination certificate C1 6,794,410 for the '410 patent, allowing new claims 2-22. On June 16, 2014, the '410 patent was assigned to Aventisub LLC. Since June 16, 2014, Aventisub has been the owner of the '410 patent. The '410 patent will expire on April 15, 2022.

26. The '346 patent, titled "Methods for Reducing the Risk of an Adverse Teriflunomide and Rosuvastatin Interaction in Multiple Sclerosis Patients," was duly and legally issued on November 17, 2015 to inventors Dietmar Weitz, Francoise Menguy-Vacheron, Pierre-Francois Clot, and Sandrine Turpault. The '346 patent was assigned to Sanofi. The '346 patent

will expire on February 4, 2034. At all times from the issuance of the '346 patent, Sanofi has been the owner of the '346 patent.

ACTS GIVING RISE TO THIS ACTION

27. Sanofi-Aventis U.S. LLC is the holder of the approved New Drug Application ("NDA") No. 202992 for the Aubagio[®] (teriflunomide), 7 mg and 14 mg, drug product ("Aubagio[®] NDA"). Sanofi-Aventis U.S. LLC, Aventisub LLC, Sanofi, and Genzyme all share in the revenue generated from the sale of Aubagio[®].

28. Aubagio[®] is indicated for the treatment of patients with relapsing forms of multiple sclerosis ("MS") ("Approved Indication") and acts to alleviate and/or slow the appearance of symptoms of an acute episode of MS, and slow the progression of an acute episode of MS. Usage of Aubagio[®] and the Approved Indication are described in the Aubagio[®] Prescribing Information, which also instructs that when Aubagio is coadministered with rosuvastatin, the dose of rosuvastatin should not exceed 10 mg once daily in patients.

29. The '410 and '346 patents are listed in the FDA publication entitled "Approved Drug Products with Therapeutic Equivalence Evaluation" (the Orange Book) as being applicable to Aubagio[®].

30. The '410 patent covers the use of Aubagio[®] according to its Approved Indication, which includes treatment of patients with relapsing forms of MS, which includes alleviating and/or slowing the appearance of symptoms of and the progression of an acute episode of MS. The '346 patent covers the use of Aubagio[®] when coadministered with rosuvastatin to manage the risk of drug interactions as described in the Aubagio[®] Prescribing Information.

31. Defendants have knowledge of the '410 and '346 patents.

32. By the Notice Letter, Glenmark USA and Glenmark SA notified Plaintiffs that Glenmark USA had submitted ANDA No. 209663 to the FDA on behalf of Glenmark SA seeking approval to engage in the commercial manufacture, importation, use, and/or sale of the Teriflunomide ANDA Products prior to the expiration of the '410 and '346 patents.

33. Glenmark USA and Glenmark SA submitted ANDA No. 209663 to obtain FDA approval to engage in the commercial manufacture, importation, use, and/or sale of the Teriflunomide ANDA Products prior to the expiration of the '410 and '346 patents.

34. On information and belief, Defendants intend to engage in the commercial manufacture, importation, use, and/or sale of the Teriflunomide ANDA Products in/into the United States and/or induce or contribute to such acts promptly upon receiving FDA approval to do so and during the term of the '410 and '346 patents.

35. In the Notice Letter, Glenmark USA and Glenmark SA notified Plaintiffs that ANDA No. 209663 contained a certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) that, in their opinion, the '410 and '346 patents are invalid, unenforceable, and/or will not be infringed by the manufacture, use, sale, offer for sale, and/or importation of the Teriflunomide ANDA Products in/into the United States ("Paragraph IV Certification").

36. In addition to the information provided to Plaintiffs in the Notice Letter, counsel for Plaintiffs reviewed the portions of ANDA No. 209663 that were voluntarily provided by Glenmark USA and Glenmark SA under the terms of a confidentiality agreement.

37. On information and belief, the active ingredient of the Teriflunomide ANDA Products is teriflunomide, which is the same active ingredient in Aubagio[®] and the same active ingredient used in the methods of one or more claims of the '410 and '346 patents.

38. On information and belief, Glenmark USA and Glenmark SA asserted in ANDA No. 209663 that the Teriflunomide ANDA Products are bioequivalent to Aubagio®.

39. On information and belief, ANDA No. 209663 refers to and relies upon the Aubagio® NDA and contains data that, according to Glenmark USA and Glenmark SA, demonstrate the bioequivalence of the Teriflunomide ANDA Products and Aubagio®.

40. On information and belief, Glenmark USA and Glenmark SA are seeking approval to market the Teriflunomide ANDA Products for the same Approved Indication as Aubagio®.

41. On information and belief, Glenmark USA and Glenmark SA are seeking approval to market the Teriflunomide ANDA Products for the treatment of patients with relapsing forms of multiple sclerosis, which includes alleviating and/or slowing the appearance of symptoms of an acute episode of MS, and slowing the progression of an acute episode of MS.

42. On information and belief, Glenmark USA and Glenmark SA are seeking approval to market the Teriflunomide ANDA Products that, when coadministered with rosuvastatin, will be used such that the dose of rosuvastatin will not exceed 10 mg once daily in patients.

43. On information and belief, Glenmark Ltd. was actively involved in the preparation and/or submission of ANDA No. 209663 including the Paragraph IV certification against the '410 and '346 patents.

44. On information and belief, Glenmark Ltd. actively and knowingly provided Glenmark USA and Glenmark SA with material information and support in preparing and submitting ANDA No. 209663 and have therefore aided and/or abetted in the filing of ANDA No. 209663.

45. On information and belief, Defendants will work in concert with one another to commercially manufacture, use, offer for sale, and/or sell the Teriflunomide ANDA Products throughout the United States, import the Teriflunomide ANDA Products into the United States, and/or induce and/or contribute to such acts promptly upon receiving FDA approval to do so and during the term of the '410 and '346 patents.

46. On information and belief, Defendants will knowingly accompany the Teriflunomide ANDA Products with prescribing information that will contain instructions for use that substantially copy the instructions for Aubagio[®], including instructions for administering the Teriflunomide ANDA Products as claimed in at least one of the claims, including but not limited to claim 10, of the '410 patent and at least one of the claims, including but not limited to claim 5, of the '346 patent.

47. On information and belief, Defendants' prescribing information for the Teriflunomide ANDA Products will instruct users to administer the Teriflunomide ANDA Products to treat patients with relapsing forms of multiple sclerosis, which includes alleviating and/or slowing the appearance of symptoms of an acute episode of MS, or slowing the progression of an acute episode of MS.

48. On information and belief, Defendants' prescribing information for the Teriflunomide ANDA Products will instruct users to administer the Teriflunomide ANDA Products to treat multiple sclerosis while managing the risk of teriflunomide and rosuvastatin drug interaction when coadministered.

49. On information and belief, Defendants have knowledge and/or an expectation that the Teriflunomide ANDA Products will be used in accordance with its prescribing information.

50. On information and belief, Defendants know that the prescribing information that will accompany the Teriflunomide ANDA Products will induce and/or contribute to others using the Teriflunomide ANDA Products in the manner set forth in the prescribing information.

51. On information and belief, physicians, health care providers, and/or patients will directly infringe one or more claims of the '410 and '346 patents by using the Teriflunomide ANDA Products in accordance with the prescribing information provided by Defendants after the FDA approves ANDA No. 209663.

52. On information and belief, Defendants specifically intend that physicians, health care providers, and/or patients will use the Teriflunomide ANDA Products in accordance with the prescribing information provided by Defendants to directly infringe one or more claims of the '410 and '346 patents.

53. On information and belief, Defendants designed the Teriflunomide ANDA Products for use in a way that would infringe the '410 and '346 patents and will instruct users of the Teriflunomide ANDA Products to use the Teriflunomide ANDA Products in a way that would infringe one or more claims of the '410 and '346 patents.

54. On information and belief, the Teriflunomide ANDA Products are not staple articles or commodities of commerce suitable for substantial non-infringing use.

55. On information and belief, Defendants knowingly have taken and intend to take active steps to induce and/or contribute to physicians, health care providers, and/or patients using the Teriflunomide ANDA Products in a manner that directly infringes one or more claims of the '410 and '346 patents including, but not limited to, providing prescribing information with instructions for administering the Teriflunomide ANDA Products as claimed in one or more claims of the '410 and '346 patents.

56. Plaintiffs commenced this action within 45 days of receiving the Notice Letter.

COUNT I
INFRINGEMENT OF U.S. PATENT NO. 6,794,410

57. Plaintiffs repeat and reallege the allegations of paragraphs 1-56 as if fully set forth herein.

58. Glenmark USA and Glenmark SA's submission of ANDA No. 209663 containing the Paragraph IV Certification to obtain approval from the FDA to engage in the commercial manufacture, importation, use, or sale of the Teriflunomide ANDA Products in/into the United States prior to the expiration of the '410 patent constitutes infringement of at least one of the claims, including but not limited to claim 10, of the '410 patent under 35 U.S.C. § 271 (e)(2)(A).

59. Glenmark Ltd. actively and knowingly aided, abetted, and induced Glenmark USA and Glenmark SA to submit ANDA No. 209663 containing the Paragraph IV Certification before the expiration of the '410 patent.

60. Defendants had notice of the '410 patent at the time of their infringement. Defendants' infringement has been, and continues to be, deliberate.

61. Plaintiffs will be substantially and irreparably harmed if Defendants' infringement of the '410 patent is not enjoined. Plaintiffs do not have an adequate remedy at law.

62. This is an exceptional case within the meaning of 35 U.S.C. § 285, which warrants reimbursement of Plaintiffs' reasonable attorney fees.

COUNT II
DECLARATORY JUDGMENT OF INFRINGEMENT
OF U.S. PATENT NO. 6,794,410

63. Plaintiffs repeat and reallege the allegations of paragraphs 1-62 as if fully set forth herein.

64. This claim arises under the Patent Laws, 35 U.S.C. § 1 *et seq.*, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202, based upon an actual controversy between the parties. Defendants have taken immediate and active steps, through the submission of ANDA No. 209663, to obtain approval from the FDA to commercially manufacture, import, use, or sell the Teriflunomide ANDA Products prior to the expiration of the '410 patent.

65. After obtaining FDA approval, Defendants plan to act in concert with each other to commercially manufacture, use, offer for sale, and/or sell the Teriflunomide ANDA Products in the United States, import the Teriflunomide ANDA Products into the United States, and/or induce or contribute to such acts prior to the expiration of the '410 patent.

66. Upon FDA approval of ANDA No. 209663, Defendants will infringe one or more of the claims, including but not limited to claim 10, of the '410 patent under §§ 271 (a), (b), or (c) by making, using, selling, offering for sale, or importing the Teriflunomide ANDA Products in/into the United States and/or inducing or contributing to such acts prior to the expiration of '410 patent, unless enjoined by this Court. Accordingly, an actual and immediate controversy exists between the parties regarding infringement of the '410 patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).

67. Upon FDA approval of ANDA No. 209663, use of the Teriflunomide ANDA Products as directed by the instructions to be included with the Teriflunomide ANDA Products will directly infringe at least one of the claims, including but not limited to claim 10, of the '410 patent either literally or under the doctrine of equivalents, under 35 U.S.C. § 271 (a), unless enjoined by this Court.

68. Defendants have taken and intend to take active steps to induce or contribute to the direct infringement of one or more claims, including but not limited to claim 10, of the '410

patent under 35 U.S.C. § 271 (b) and/or § 271 (c) after ANDA No. 209663 is approved, unless enjoined by this Court.

69. Defendants have knowledge of the ‘410 patent and, by the prescribing information that will be included with Teriflunomide ANDA Products, know or should know that they will aid and abet another’s direct infringement of at least one of the claims, including but not limited to claim 10, of the ‘410 patent either literally or under the doctrine of equivalents.

70. Defendants’ offering for sale, sale, and/or importation of the Teriflunomide ANDA Products in/into the United States with the prescribing information for the Teriflunomide ANDA Products will actively induce infringement of at least one of the claims, including but not limited to claim 10, of the ‘410 patent either literally or under the doctrine of equivalents, under 35 U.S.C. § 271 (b).

71. The use of the Teriflunomide ANDA Products constitutes a material part of at least one of the claims, including but not limited to claim 10, of the ‘410 patent; Defendants know that the Teriflunomide ANDA Products are especially made or adapted for use in infringing at least one of the claims, including but not limited to claim 10, of the ‘410 patent either literally or under the doctrine of equivalents; and Defendants know that the Teriflunomide ANDA Products are not staple articles of commerce or commodities of commerce suitable for substantial noninfringing use.

72. Defendants’ manufacture, use, offering for sale, sale, and/or importation of the Teriflunomide ANDA Products in/into the United States will contributorily infringe at least one of the claims, including but not limited to claim 10, of the ‘410 patent either literally or under the doctrine of equivalents, under 35 U.S.C. § 271 (c).

73. Defendants will have notice of the '410 patent at the time of their infringement. Defendants' infringement of the '410 patent will be deliberate.

74. Plaintiffs will be substantially and irreparably harmed if Defendants' infringement is not enjoined. Plaintiffs do not have an adequate remedy at law.

75. This is an exceptional case within the meaning of 35 U.S.C. § 285, which warrants reimbursement of Plaintiffs' reasonable attorney fees.

COUNT III
INFRINGEMENT OF U.S. PATENT NO. 9,186,346

76. Plaintiffs repeat and reallege the allegations of paragraphs 1-75 as if fully set forth herein.

77. Glenmark USA and Glenmark SA's submission of ANDA No. 209663 containing the Paragraph IV Certification to obtain approval from the FDA to engage in the commercial manufacture, importation, use, or sale of the Teriflunomide ANDA Products in/into the United States prior to the expiration of the '346 patent constitutes infringement of at least one of the claims, including but not limited to claim 5, of the of the '346 patent under 35 U.S.C. § 271 (e)(2)(A).

78. Glenmark Ltd. actively and knowingly aided, abetted, and induced Glenmark USA and Glenmark SA to submit ANDA No. 209663 containing the Paragraph IV Certification before the expiration of the '346 patent.

79. Defendants had notice of the '346 patent at the time of their infringement. Defendants' infringement has been, and continues to be, deliberate.

80. Plaintiffs will be substantially and irreparably harmed if Defendants' infringement of the '346 patent is not enjoined. Plaintiffs do not have an adequate remedy at law.

81. This is an exceptional case within the meaning of 35 U.S.C. § 285, which warrants reimbursement of Plaintiffs' reasonable attorney fees.

**COUNT IV
DECLARATORY JUDGMENT OF INFRINGEMENT
OF U.S. PATENT NO. 9,186,346**

82. Plaintiffs repeat and reallege the allegations of paragraphs 1-81 as if fully set forth herein.

83. This claim arises under the Patent Laws, 35 U.S.C. § 1 *et seq.*, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202, based upon an actual controversy between the parties. Defendants have taken immediate and active steps, through the submission of ANDA No. 209663, to obtain approval from the FDA to commercially manufacture, import, use, or sell the Teriflunomide ANDA Products prior to the expiration of the '346 patent.

84. After obtaining FDA approval, Defendants plan to act in concert with each other to commercially manufacture, use, offer for sale, and/or sell the Teriflunomide ANDA Products in the United States, import the Teriflunomide ANDA Products into the United States, and/or induce or contribute to such acts prior to the expiration of the '346 patent.

85. Upon FDA approval of ANDA No. 209663, Defendants will infringe one or more of the claims of the '346 patent under §§ 271 (a), (b), or (c) by making, using, selling, offering for sale, or importing the Teriflunomide ANDA Products in/into the United States and/or inducing or contributing to such acts prior to the expiration of '346 patent, unless enjoined by this Court. Accordingly, an actual and immediate controversy exists between the parties regarding infringement of the '346 patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).

86. Upon FDA approval of ANDA No. 209663, use of the Teriflunomide ANDA Products as directed by the instructions to be included with the Teriflunomide ANDA Products

will directly infringe at least one of the claims, including but not limited to claim 5, of the '346 patent either literally or under the doctrine of equivalents, under 35 U.S.C. § 271 (a), unless enjoined by this Court.

87. Defendants have taken and intend to take active steps to induce or contribute to the direct infringement of one or more claims, including but not limited to claim 5, of the '346 patent under 35 U.S.C. § 271 (b) and/or § 271 (c) after ANDA No. 209663 is approved, unless enjoined by this Court.

88. Defendants have knowledge of the '346 patent and, by the prescribing information that will be included with Teriflunomide ANDA Products, know or should know that they will aid and abet another's direct infringement of at least one of the claims, including but not limited to claim 5, of the '346 patent either literally or under the doctrine of equivalents.

89. Defendants' offering for sale, sale, and/or importation of the Teriflunomide ANDA Products in/into the United States with the prescribing information for the Teriflunomide ANDA Products will actively induce infringement of at least one of the claims, including but not limited to claim 5, of the '346 patent either literally or under the doctrine of equivalents, under 35 U.S.C. § 271 (b).

90. The use of the Teriflunomide ANDA Products constitutes a material part of at least one of the claims, including but not limited to claim 5, of the '346 patent; Defendants know that the Teriflunomide ANDA Products are especially made or adapted for use in infringing at least one of the claims, including but not limited to claim 5, of the '346 patent either literally or under the doctrine of equivalents; and Defendants know that the Teriflunomide ANDA Products are not staple articles of commerce or commodities of commerce suitable for substantial noninfringing use.

91. Defendants' manufacture, use, offering for sale, sale, and/or importation of the Teriflunomide ANDA Products in/into the United States will contributorily infringe at least one of the claims, including but not limited to claim 5, of the '346 patent either literally or under the doctrine of equivalents, under 35 U.S.C. § 271 (c).

92. Defendants will have notice of the '346 patent at the time of their infringement. Defendants' infringement of the '346 patent will be deliberate.

93. Plaintiffs will be substantially and irreparably harmed if Defendants' infringement is not enjoined. Plaintiffs do not have an adequate remedy at law.

94. This is an exceptional case within the meaning of 35 U.S.C. § 285, which warrants reimbursement of Plaintiffs' reasonable attorney fees.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request the following relief:

(a) A judgment declaring that Defendants have infringed one or more claims of the '410 and '346 patents by the filing of ANDA No. 209663;

(b) A judgment declaring that Defendants' manufacturing, using, selling, offering for sale, or importing the Teriflunomide ANDA Products in/into the United States will infringe one or more claims of the '410 and '346 patents;

(c) A judgment under 35 U.S.C. § 271 (e)(4)(A) providing that the effective date of any FDA approval of ANDA No. 209663 under Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)) be a date no earlier February 4, 2034, the expiration date of the '346 patent, which is the latest expiring of the infringed patents, or the expiration of any other exclusivity to which Plaintiffs are or become entitled;

(d) Injunctive relief under 35 U.S.C. § 271 (e)(4)(B) preliminarily and permanently enjoining Defendants from making, using, selling, offering for sale, or importing the Teriflunomide ANDA Products in/into the United States until after expiration of the ‘410 and ‘346 patents or the expiration of any other exclusivity to which Plaintiffs are or become entitled;

(e) A permanent injunction pursuant to 35 U.S.C. § 271 (e)(4)(B) restraining and enjoining Defendants from practicing any methods as claimed in the ‘410 and ‘346 patents, or from actively inducing or contributing to the infringement of any claim of the ‘410 and ‘346 patents, until after the expiration of the ‘410 and ‘346 patents or the expiration of any other exclusivity to which Plaintiffs are or become entitled;

(f) A Declaration that the commercial manufacture, use, sale, offer for sale, and importation in/into the United States of the Teriflunomide ANDA Products will directly infringe, induce, and/or contribute to infringement of the ‘410 and ‘346 patents;

(g) Damages under 35 U.S.C. § 271 (e)(4)(C), which this Court should treble pursuant to 35 U.S.C. § 284, if Defendants infringe the ‘410 and ‘346 patents by engaging in the commercial manufacture, importation, use, sale, offer for sale, or import the Teriflunomide ANDA Products in/into the United States prior to the expiration of the ‘410 and ‘346 patents or the expiration of any other exclusivity to which Plaintiffs are or become entitled;

(h) An award of reasonable attorney fees in this action pursuant to 35 U.S.C. § 285;

(i) Costs and expenses in this action; and

(j) Such further and other relief as this Court may deem just and proper.

DATED: December 29, 2016

RATNERPRESTIA

/s/ Jeffrey B. Bove

Jeffrey B. Bove (# 998)

Karen R. Poppel (# 5373)

Nemours Building

1007 North Orange Street, Suite 205

Wilmington, DE 19801

(302) 888-6241

jbove@ratnerprestia.com

kpoppel@ratnerprestia.com

Attorneys for Plaintiffs

sanofi-aventis U.S. LLC, Aventisub LLC,

Sanofi, and Genzyme Corporation

Of Counsel:

Paul H. Berghoff

Alison J. Baldwin

Paula S. Fritsch

MCDONNELL BOEHNEN

HULBERT & BERGHOFF LLP

(312) 913-0001

300 South Wacker Drive

Chicago, Illinois 60614

berghoff@mbhb.com

baldwin@mbhb.com

fritsch@mbhb.com

3446969_1